Tradestie Institutional Equity Comparison Engine

CRSP vs EDIT โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CRSP Overall Edge

CRSP Captures Institutional Edge (3โ€“1 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to CRISPR Therapeutics AG (CRSP) driven by superior Valuation, Growth & Margin, Momentum & Technical while EDIT counters with relative strength in Options & Structure. Fundamentally, CRSP trades at 23.4x Forward P/E with -2058.6% operating margin (+1325.1% YoY revenue) versus EDIT at N/M Forward P/E and -167.0% operating margin (+37.4% YoY). In options structure, CRSP sits in BREAKDOWN (52nd %ile IV; Dealer Gamma Walls on Pro) against EDIT sits in BREAKDOWN (38th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner CRSP
CRSP 23.4x vs EDIT N/M Fwd P/E
Growth & Margin Winner CRSP
Op Margin -2058.6% vs -167.0% ยท YoY +1325.1% vs +37.4%
Momentum & Technical Winner CRSP
1Y -20.5% vs -25.0% ยท 52W Pos 1% vs 11%
Options & Structure Winner EDIT
BREAKDOWN (52nd %ile IV) vs BREAKDOWN (38th %ile IV)
CRSP NASDAQ
CRISPR Therapeutics AG
Biological Products, (No Disgnostic Substances)
$40.61
-3.86% 1D
Market Cap $4.1B
1M Return -17.54%
1Y Return -20.54%
Forward P/E 23.4x
Unified AI Score
48.6 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 68.0 Mom 60.0
EDIT NASDAQ
Editas Medicine, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$1.91
-12.21% 1D
Market Cap $336.5M
1M Return -18.94%
1Y Return -25.0%
Forward P/E N/M
Unified AI Score
51.6 / 100 HOLD
Tech 40.0 Fund 54.0 Flow 69.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CRSP -20.54% EDIT -25.0% Spread: +4.46 pp (CRSP Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period CRSP Revenue EDIT Revenue CRSP Op. Margin EDIT Op. Margin Margin Edge
FY2018 $0M $30M -5087.8% -356.1% EDIT
FY2019 $290M $20M 16.1% -686.4% CRSP
FY2020 $0M $90M -49295.5% -148.6% EDIT
FY2021 $910M $30M 40.8% -756.1% CRSP
FY2022 $0M $20M -56190.4% -1146.3% EDIT
FY2023 $370M $80M -60.0% -216.6% CRSP
FY2024 $40M $30M -1250.4% -777.2% EDIT
FY2025 $0M $40M -18933.6% -394.9% EDIT

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CRSP (7) vs EDIT (3)
Institutional Metric CRSP EDIT Criterion Row Winner
Market Capitalization Scale $4.1B $336.5M Larger Scale CRSP
Trailing P/E Ratio Valuation 23.4x N/M Lower Multiple CRSP
Forward P/E Ratio Valuation 23.4x N/M Lower Multiple CRSP
Revenue Growth (YoY) Growth +1325.1% +37.4% Higher Growth CRSP
Operating Margin (TTM) Profitability -2058.6% -167.0% Higher Margin EDIT
Net Profit Margin Profitability 0.0% -144.9% Higher Margin CRSP
Return on Equity (ROE) Capital Efficiency -25.6% -147.4% Higher ROE CRSP
52-Week Range Position Momentum 1% ($40โ€“$63) 11% ($2โ€“$4) Stronger Trend EDIT
Beta / 30D Volatility Risk Regime 1.85ฮฒ ยท 60% Vol 2.32ฮฒ ยท 102% Vol Lower Realized Risk CRSP
Unified Institutional Score Composite Signal 48.6 / 100 (HOLD) 51.6 / 100 (HOLD) Higher Composite EDIT

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CRSP vs EDIT Buy Guide
CRSP BREAKDOWN
58d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 52nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live CRSP Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
EDIT BREAKDOWN
146d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 38th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live EDIT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CRSP nor EDIT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.